NEW DELHI: The Union health ministry on Tuesday amended drug regulations to end the over-the-counter sale of syrup-based medicines, including cough syrups, making a doctor's prescription mandatory for ...
As one of the many biotech stocks investors are watching, Ocular Therapeutix focuses on treating retinal diseases. Its lead commercial product, Dextenza, is an insert for treating inflammation and ...
June 9 (Reuters) - Drug developer Parabilis Medicines is targeting a valuation of up to nearly $2.3 billion in its upsized initial public offering in the U.S., as biotech ‌IPOs continue to run hot.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results